In the booming tech sector, a specific subdivision – biotechnologies – is also getting investor attention. Although the companies on our list today are not generating any revenues, investors clearly see future potential, as some of these companies are receiving valuations in excess of $200 million.
biOasis Technologies Inc. (TSXV: BTI) – $1.18
Biotechnology & Medical Research
biOasis Technologies Inc. is an early-stage biopharmaceutical company that is focused on research, development and commercialization of technologies and products intended for the treatment of central nervous system (CNS) diseases and diseases of the brain. It is engaged in the development of vectors, such as Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB).
- Market Cap: $52,911,403
- Revenues (LTM): $0
- 5/30 Day Average Volume % Change: 7.3%
- YTD Price Change: 6.2%
Related: 6 Biotech/Pharma Stocks with ‘Unhealthy’ Valuations >>
Helix Biopharma Corp. (TSX: HBP) – $2.06
Biotechnology & Medical Research
Helix BioPharma Corporation is a Canada-based biopharmaceutical company focused on cancer therapy. It is developing products for the treatment and prevention of cancer based on its technologies. The Company’s product development initiatives have focused on its L-DOS47 and Topical Interferon Alpha-2b new drug candidates. It operates through the biopharmaceuticals segment. The Company’s most advanced product clinically is its Topical Interferon Alpha-2b as a treatment for certain skin/mucosal lesions caused by HPV infections.
- Market Cap: $174,242,977
- Revenues (LTM): $0
- 5/30 Day Average Volume % Change: 59.9%
- YTD Price Change: 14.4%
SciVac Therapeutics Inc. (TSX: VAC) – $0.18
Biotechnology & Medical Research
SciVac Therapeutics Inc, formerly Levon Resources Ltd, is an Israel-based company primarily engaged in the biotechnology and medical research. The Company specializes in developing and marketing biopharmaceuticals, which prevent and treat infectious and immune diseases, such as Hepatitis B (HBV) and Graft-vs-Host Disease (GVHD). Its pipeline products comprise: Sci-B-Vac, a vaccine used in HBV treatment that reproduces three HVB antigens; as well as S-Graft, an enzyme-based drug implemented in GVHD treatment.
- Market Cap: $136,075,499
- Revenues (LTM): $0
- 5/30 Day Average Volume % Change: 41.6%
- YTD Price Change: -25.0%
QLT Inc. (TSX: QLT) – $3.60
Biotechnology & Medical Research
QLT Inc. (QLT) is a biotechnology company engaged in the development and commercialization of ocular products. QLT is engaged in the development of QLT091001 for the treatment of Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, a biochemical component of the visual retinoid cycle, and is used for the treatment of certain age-related and inherited retinal degenerative diseases.
- Market Cap: $187,917,435
- Revenues (LTM): $0
- 5/30 Day Average Volume % Change: 26.9%
- YTD Price Change: -23.1%
